AXL is a receptor tyrosine kinase of the TAM family, the function of which is poorly understood. We previously identified AXL overexpression in Imatinib (IM)-resistant CML cell lines and patients. The present study was conducted to investigate the role of AXL and the mechanisms underlying AXL overexpression in Tyrosine Kinase Inhibitor...
-
November 2011 (v1)Journal articleUploaded on: October 14, 2023
-
December 1, 2011 (v1)Journal article
Mitotic catastrophe (MC) is induced when stressed cells enter prematurely or inappropriately into mitosis and can be caused by ionizing radiation and anticancer drugs. Foretinib is a multikinase inhibitor whose mechanism of action is incompletely understood. We investigated here the effect of Foretinib on chronic myelogenous leukemia (CML) cell...
Uploaded on: December 2, 2022 -
April 2012 (v1)Journal article
Azacitidine is the leading compound to treat patients suffering myelodysplastic syndrome (MDS) or AML with less than 30% of blasts, but a majority of patients is primary refractory or rapidly relapses under treatment. These patients have a drastically reduced life expectancy as compared to sensitive patients. Therefore identifying predictive...
Uploaded on: October 14, 2023 -
June 11, 2013 (v1)Journal articleMonosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.
IPSS-R classifies cytogenetic abnormalities into five prognostic groups for survival. Monosomal karyotype (MK) is not a subgroup of IPSS-R. Additional prognostic information from MK in poor and very poor karyotype has been recently shown. The aim of our study was to determine the prognostic value of IPSS-R and MK for response and survival in...
Uploaded on: December 4, 2022 -
December 13, 2012 (v1)Journal article
International audience
Uploaded on: December 2, 2022 -
March 31, 2012 (v1)Journal article
Chronic myelogenous leukemia (CML) is a cytogenetic disorder resulting from the expression of p210BCR-ABL. Imatinib, an inhibitor of BCR-ABL, has emerged as the leading compound to treat CML patients. Despite encouraging clinical results, resistance to imatinib represents a major drawback for therapy, as a substantial proportion of patients are...
Uploaded on: October 14, 2023 -
August 2012 (v1)Journal articleImatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.
Chronic myelogenous leukemia (CML) is a cytogenetic disorder resulting from the expression of p210BCR-ABL. Imatinib, an inhibitor of BCR-ABL, has emerged as the leading compound to treat CML patients. Despite encouraging clinical results, resistance to imatinib represents a major drawback for therapy, as a substantial proportion of patients are...
Uploaded on: December 3, 2022